ID   BE-13
AC   CVCL_1081
SY   Be-13; BE13; Be13
DR   CLO; CLO_0001921
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03151896
DR   cancercelllines; CVCL_1081
DR   Cell_Model_Passport; SIDM01245
DR   ChEMBL-Cells; CHEMBL3308184
DR   ChEMBL-Targets; CHEMBL2366303
DR   Cosmic; 906763
DR   Cosmic; 1115589
DR   Cosmic; 1151773
DR   Cosmic; 1330495
DR   Cosmic; 1760518
DR   Cosmic; 2165705
DR   Cosmic; 2602909
DR   Cosmic-CLP; 906763
DR   DepMap; ACH-002216
DR   DSMZ; ACC-396
DR   DSMZCellDive; ACC-396
DR   EGA; EGAS00001000978
DR   GDSC; 906763
DR   GEO; GSM1669613
DR   GEO; GSM5137751
DR   IARC_TP53; 21650
DR   LINCS_LDP; LCL-1044
DR   PharmacoDB; BE13_84_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1081
DR   Wikidata; Q54795852
RX   CelloPub=CLPUB00700;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1727382;
RX   PubMed=2144611;
RX   PubMed=6181032;
RX   PubMed=6331881;
RX   PubMed=12592342;
RX   PubMed=15361874;
RX   PubMed=15472075;
RX   PubMed=20164919;
RX   PubMed=20143388;
RX   PubMed=22675565;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35354797;
RX   PubMed=35839778;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a Peer derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the bone marrow of a 11 year old patient with T-ALL.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00178.
CC   Population: Caucasian.
CC   Doubling time: ~40-60 hours (DSMZ=ACC-396).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 34 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (PubMed=22675565).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.02%; Native American=1.38%; East Asian, North=0%; East Asian, South=1.18%; South Asian=10.89%; European, North=13.65%; European, South=69.88% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,14
ST   D16S539: 8,13
ST   D18S51: 11,15
ST   D19S433: 13,17
ST   D21S11: 28,33.2
ST   D2S1338: 20
ST   D3S1358: 15
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 15
ST   FGA: 24
ST   Penta D: 11,13
ST   Penta E: 12,15
ST   TH01: 7,8
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1913 ! Peer
SX   Female
AG   4Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   CelloPub=CLPUB00700;
RA   Galili N., Galili U., Ravid Z., Schlesinger M., Goldblum N.;
RT   "Induction of differentiation with phorbol ester in a human T cell line
RT   (Be13) expressing both prothymocyte and thymocyte characteristics.";
RL   Hum. Lymph. Diff. 1:123-130(1981).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1727382;
RA   Cheng J., Yee J.-K., Yeargin J., Friedmann T., Haas M.;
RT   "Suppression of acute lymphoblastic leukemia by the human wild-type
RT   p53 gene.";
RL   Cancer Res. 52:222-226(1992).
//
RX   PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990;
RA   Cheng J., Haas M.;
RT   "Frequent mutations in the p53 tumor suppressor gene in human leukemia
RT   T-cell lines.";
RL   Mol. Cell. Biol. 10:5502-5509(1990).
//
RX   PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4;
RA   Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H.,
RA   Schlesinger M.;
RT   "Antigens specific for human T-lymphocytes detected by xenoantisera to
RT   HD-MAR cells: their differential expression on various T-cell lines.";
RL   Hum. Immunol. 4:219-228(1982).
//
RX   PubMed=6331881;
RA   Galili U., Peleg A., Milner Y., Galili N.;
RT   "Be13, a human T-leukemia cell line highly sensitive to
RT   dexamethasone-induced cytolysis.";
RL   Cancer Res. 44:4594-4601(1984).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=15361874; DOI=10.1038/ng1425;
RA   Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A.A., Levine R.,
RA   Vermeesch J.R., Stul M., Dutta B., Boeckx N., Bosly A., Heimann P.,
RA   Uyttebroeck A., Mentens N., Somers R., MacLeod R.A.F., Drexler H.G.,
RA   Look A.T., Gilliland D.G., Michaux L., Vandenberghe P., Wlodarska I.,
RA   Marynen P., Hagemeijer A.;
RT   "Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute
RT   lymphoblastic leukemia.";
RL   Nat. Genet. 36:1084-1089(2004).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//